跳至主要内容
临床试验/NCT02130518
NCT02130518Unknown2 期

A Multicenter, Randomized, Double-Blind, Efficacy Study of Auriclosene Irrigation Solution on Indwelling Urinary Catheter Patency

NovaBay Pharmaceuticals, Inc.17 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2014年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
140
试验地点
17
主要终点
Percent flow rate reduction of study catheters at time of removal

研究概览

简要总结

Long-term indwelling urinary catheters are associated with chronic recurrent urinary tract infections and blockage caused by crystalline biofilm accumulation (encrustation) of the catheter surfaces. When the urine and catheter are colonized by urease-producing bacteria such as Proteus mirabilis, encrustation of the catheter is likely to occur.

The use of a catheter irrigation solution that can prevent biofilm formation and encrustation leading to blockage may keep the catheter patent longer, resulting in fewer catheter changes, potentially lower incidence of UTIs and better patient quality of life.

Auriclosene is a non-antibiotic, fast-acting, broad-spectrum antimicrobial, which exhibits potential for the rapid decolonization of a range of urologic pathogens, including the urease-producing Proteus mirabilis.

Subjects will be randomized to either Auriclosene Irrigation Solution or Auriclosene Vehicle solution.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject requiring an indwelling urinary catheter with a history of catheter blockage and/or encrustation
  • Screening within 30 days of randomization

排除标准

  • Systemic antibiotic use within 14 days of first treatment
  • Investigational drug or device within 30 days if enrollment
  • Current infection requiring treatment with systemic antibiotics
  • Pregnant or lactating female

研究组 & 干预措施

Auriclosene (AIS)

Experimental

Auriclosene Irrigation Solution, 0.2%, 8 treatments over 4 weeks

干预措施: Auriclosene Irrigation Solution, 0.2% (Drug)

Auriclosene Vehicle Solution

Placebo Comparator

Auriclosene Vehicle Solution, 8 treatments over 4 weeks

干预措施: Auriclosene Vehicle Solution (Drug)

结局指标

主要结局

Percent flow rate reduction of study catheters at time of removal

时间窗: Up to 29 Days

次要结局

  • Number of study catheters removed due to clinical catheter blockage(Up to 29 days)
  • Number of subjects with serious and non-serious adverse events(Up to 29 Days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (17)

Loading locations...

相似试验